- Home
- EDHL vs EPRX Comparison
EDHL vs EPRX Comparison
Compare EDHL & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDHL
- EPRX
- Stock Information
- Founded
- EDHL 2021
- EPRX 2011
- Country
- EDHL Hong Kong
- EPRX Canada
- Employees
- EDHL N/A
- EPRX N/A
- Industry
- EDHL
- EPRX
- Sector
- EDHL
- EPRX
- Exchange
- EDHL NYSE
- EPRX NYSE
- Market Cap
- EDHL 101.8M
- EPRX 111.1M
- IPO Year
- EDHL 2025
- EPRX N/A
- Fundamental
- Price
- EDHL $4.07
- EPRX $3.80
- Analyst Decision
- EDHL
- EPRX Strong Buy
- Analyst Count
- EDHL 0
- EPRX 1
- Target Price
- EDHL N/A
- EPRX $9.00
- AVG Volume (30 Days)
- EDHL 510.6K
- EPRX 15.4K
- Earning Date
- EDHL 01-01-0001
- EPRX 05-06-2025
- Dividend Yield
- EDHL N/A
- EPRX N/A
- EPS Growth
- EDHL N/A
- EPRX N/A
- EPS
- EDHL 0.58
- EPRX N/A
- Revenue
- EDHL $4,089,375.00
- EPRX N/A
- Revenue This Year
- EDHL N/A
- EPRX N/A
- Revenue Next Year
- EDHL N/A
- EPRX N/A
- P/E Ratio
- EDHL $6.96
- EPRX N/A
- Revenue Growth
- EDHL 246.65
- EPRX N/A
- 52 Week Low
- EDHL N/A
- EPRX $2.20
- 52 Week High
- EDHL N/A
- EPRX $4.48
- Technical
- Relative Strength Index (RSI)
- EDHL N/A
- EPRX N/A
- Support Level
- EDHL N/A
- EPRX N/A
- Resistance Level
- EDHL N/A
- EPRX N/A
- Average True Range (ATR)
- EDHL 0.00
- EPRX 0.00
- MACD
- EDHL 0.00
- EPRX 0.00
- Stochastic Oscillator
- EDHL 0.00
- EPRX 0.00
About EDHL EVERBRIGHT DIGITAL HOLDING
Everbright Digital Holding Ltd is an integrated marketing solutions provider in Hong Kong that is involved in the metaverse and related technologies, and is providing one-stop digital marketing services for the process of enterprise development. Its digital marketing solutions include metaverse stimulation, virtual reality (VR) and augmented reality (AR) design and creation, creative event planning and management, IP character creation and social media marketing.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.